MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer

Completed · Not applicable

Conditions studied: Prostate Cancer

In brief

Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity.

Key facts

Study ID

NCT03664193

Run by

Weill Medical College of Cornell University

People needed

30

Starts

2018-08-24

Expected to finish

2020-01-28

Last updated by the study team

2021-01-05

Who can join

Age: 18 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy-proven diagnosis of prostate adenocarcinoma
• NCCN defined low-, intermediate- and high-risk prostate cancer
• Age ≥ 18
• Patient must have prostate MRI with a PIRADS 3-5 lesion or PSMA positron emission tomography (PET) with an avid intraprostatic lesion

You may not qualify if…

• History of prior pelvic radiation (external beam or brachytherapy)
• Inability to undergo MRI
• Patients with metastatic disease (other than pelvic lymph nodes) are ineligible for this study
• American Urological Association (AUA) score >17 - AUA score >17

Where it is running

• Weill Cornell Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.